Your browser doesn't support javascript.
loading
Purpuric drug eruption without leukocytoclastic vasculitis associated with vancomycin.
Nakamura, Tamaki; Wakiguchi, Hiroyuki; Okazaki, Fumiko; Asano, Nobuyuki; Hoshii, Yoshinobu; Hasegawa, Shunji.
Afiliação
  • Nakamura T; Department of Pediatrics, Yamaguchi University Graduate School of Medicine, 1-1-1 Minamikogushi, Ube, Yamaguchi 755-8505, Japan.
  • Wakiguchi H; Department of Pediatrics, Yamaguchi University Graduate School of Medicine, 1-1-1 Minamikogushi, Ube, Yamaguchi 755-8505, Japan.
  • Okazaki F; Department of Pediatrics, Yamaguchi University Graduate School of Medicine, 1-1-1 Minamikogushi, Ube, Yamaguchi 755-8505, Japan.
  • Asano N; Department of Dermatology, Yamaguchi University Graduate School of Medicine, 1-1-1 Minamikogushi, Ube, Yamaguchi 755-8505, Japan.
  • Hoshii Y; Department of Diagnostic Pathology, Yamaguchi University Hospital, 1-1-1 Minamikogushi, Ube, Yamaguchi 755-8505, Japan.
  • Hasegawa S; Department of Pediatrics, Yamaguchi University Graduate School of Medicine, 1-1-1 Minamikogushi, Ube, Yamaguchi 755-8505, Japan.
Asian Pac J Allergy Immunol ; 38(1): 47-51, 2020 Mar.
Article em En | MEDLINE | ID: mdl-30447655
Vancomycin (VCM) has been reported to elicit adverse cutaneous drug reactions. However, VCM-associated purpuric drug eruption has not been reported yet, except leukocytoclastic vasculitis. A 16-year-old Japanese girl was admitted with a respiratory infection. We initiated intravenous administration of VCM. After the start of treatment, impalpable purpuric eruption appeared on her trunk. The eruption gradually extended to her neck, legs, and arms. Skin biopsy showed vasculitis with lymphocyte infiltration in the superficial dermis. A drug lymphocyte stimulation test yielded positive results for VCM. Her cutaneous symptoms rapidly reversed after the withdrawal of VCM. To the best of our knowledge, this is the first reported case of VCM-associated purpuric drug eruption, which differs from leukocytoclastic vasculitis. We recommend that VCM-associated purpuric drug eruption should be considered in the differential diagnosis during the administration of VCM, and a drug lymphocyte stimulation test may be useful for assessment of pathogenesis.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Púrpura / Vancomicina / Toxidermias País/Região como assunto: Asia Idioma: En Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Japão

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Púrpura / Vancomicina / Toxidermias País/Região como assunto: Asia Idioma: En Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Japão